Cross-Reactive Immune Response Induced by the Vi Capsular Polysaccharide Typhoid Vaccine Against Salmonella Paratyphi Strains

Scandinavian Journal of Immunology

Volumn 79, Issue 3, 2014, Pages 222-229

  Pakkanen, S H ^a,b   Kantele, J M ^c   Kantele, A ^a,b,d  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

^d UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; TYPHOID VACCINE;

ADULT; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DRUG PURIFICATION; DRUG SYNTHESIS; FEMALE; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MALE; MIDDLE AGED; PARATYPHOID FEVER; PLASMA CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SALMONELLA PARATYPHI; SALMONELLA PARATYPHI B; SALMONELLA PARATYPHI C; VACCINATION; YOUNG ADULT;

ADULT; ANTIBODIES, BACTERIAL; CROSS REACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; O ANTIGENS; PARATYPHOID FEVER; POLYSACCHARIDES, BACTERIAL; SALMONELLA PARATYPHI A; SALMONELLA PARATYPHI B; SALMONELLA PARATYPHI C; TYPHOID-PARATYPHOID VACCINES; VACCINATION; YOUNG ADULT;

EID: 84894440102     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12151     Document Type: Article

References (50)

1. Fangtham M, Wilde H. Emergence of Salmonella paratyphi A as a major cause of enteric fever: need for early detection, preventive measures, and effective vaccines. J Travel Med 2008;15:344-50.
2. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg 2008;102:91-5.
3. Connor BA, Schwartz E. Typhoid and paratyphoid fever in travellers. Lancet Infect Dis 2005;5:623-8.
4. Ekdahl K, de Jong B, Andersson Y. Risk of travel-associated typhoid and paratyphoid fevers in various regions. J Travel Med 2005;12:197-204.
5. Dong BQ, Yang J, Wang XY et al. Trends and disease burden of enteric fever in Guangxi province, China, 1994-2004. Bull World Health Organ 2010;88:689-96.
6. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet 2005;366:749-62.
7. Whitaker JA, Franco-Paredes C, del Rio C, Edupuganti S. Rethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areas. J Travel Med 2009;16:46-52.
8. Chandel DS, Chaudhry R, Dhawan B, Pandey A, Dey AB. Drug-resistant Salmonella enterica serotype paratyphi A in India. Emerg Infect Dis 2000;6:420-1.
9. Threlfall EJ, Fisher IS, Berghold C et al. Trends in antimicrobial drug resistance in Salmonella enterica serotypes Typhi and Paratyphi A isolated in Europe, 1999-2001. Int J Antimicrob Agents 2003;22:487-91.
10. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ 2004;82:346-53.
11. Pakkanen SH, Kantele JM, Kantele A. Cross-reactive gut-directed immune response against Salmonella Paratyphi A and B in typhoid fever and after oral Ty21a typhoid vaccination. Vaccine 2012;30:6047-53.
12. Levine MM, Ferreccio C, Black RE, Lagos R, San Martin O, Blackwelder WC. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin Infect Dis 2007;45 (Suppl 1):S24-8.
13. Meltzer E, Sadik C, Schwartz E. Enteric fever in Israeli travelers: a nationwide study. J Travel Med 2005;12:275-81.
14. Tagliabue A, Villa L, De Magistris MT et al. IgA-driven T cell-mediated anti-bacterial immunity in man after live oral Ty 21a vaccine. J Immunol 1986;137:1504-10.
15. D'Amelio R, Tagliabue A, Nencioni L et al. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect Immun 1988;56:2731-5.
16. Nisini R, Biselli R, Matricardi PM, Fattorossi A, D'Amelio R. Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. Vaccine 1993;11:582-6.
17. Wahid R, Simon R, Zafar SJ, Levine MM, Sztein MB. Live oral typhoid vaccine Ty21a induces cross-reactive humoral immune responses against Salmonella enterica serovar Paratyphi A and S. Paratyphi B in humans. Clin Vaccine Immunol 2012;19:825-34.
18. Guzman CA, Borsutzky S, Griot-Wenk M et al. Vaccines against typhoid fever. Vaccine 2006;24:3804-11.
19. Kantele A, Pakkanen SH, Kantele JM. Head-to-head comparison of humoral immune responses to Vi capsular polysaccharide and Salmonella Typhi Ty21a typhoid vaccines. PLoS ONE 2013;8:e60583.
20. Mora JR, von Andrian UH. Differentiation and homing of IgA-secreting cells. Mucosal Immunol 2008;1:96-109.
21. Kantele A. Antibody-secreting cells in the evaluation of the immunogenicity of an oral vaccine. Vaccine 1990;8:321-6.
22. Kantele A, Kantele JM, Savilahti E et al. Homing potentials of circulating lymphocytes in humans depend on the site of activation: oral, but not parenteral, typhoid vaccination induces circulating antibody-secreting cells that all bear homing receptors directing them to the gut. J Immunol 1997;158:574-9.
23. Kantele A, Häkkinen M, Moldoveanu Z et al. Differences in immune responses induced by oral and rectal immunizations with Salmonella typhi Ty21a: evidence for compartmentalization within the common mucosal immune system in humans. Infect Immun 1998;66:5630-5.
24. Kantele A, Arvilommi H, Iikkanen K et al. Unique characteristics of the intestinal immune system as an inductive site after antigen reencounter. J Infect Dis 2005;191:12-7.
25. Lundgren A, Kaim J, Jertborn M. Parallel analysis of mucosally derived B- and T-cell responses to an oral typhoid vaccine using simplified methods. Vaccine 2009;27:4529-36.
26. Pakkanen SH, Kantele JM, Moldoveanu Z et al. Expression of homing receptors on IgA1 and IgA2 pre-plasma cells in blood reflects differential distribution of IgA1 and IgA2 in various body fluids. Clin Vaccine Immunol 2010;17:393-401.
27. Kantele A, Westerholm M, Kantele JM, Mäkelä PH, Savilahti E. Homing potentials of circulating antibody-secreting cells after administration of oral or parenteral protein or polysaccharide vaccine in humans. Vaccine 1999;17:229-36.
28. Kantele A, Arvilommi H, Kantele JM, Rintala L, Mäkelä PH. Comparison of the human immune response to live oral, killed oral or killed parenteral Salmonella typhi TY21A vaccines. Microb Pathog 1991;10:117-26.
29. Kantele A, Mäkelä PH. Different profiles of the human immune response to primary and secondary immunization with an oral Salmonella typhi Ty21a vaccine. Vaccine 1991;9:423-7.
30. Kantele A, Papunen R, Virtanen E et al. Antibody-secreting cells in acute urinary tract infection as indicators of local immune response. J Infect Dis 1994;169:1023-8.
31. Kantele AM, Takanen R, Arvilommi H. Immune response to acute diarrhea seen as circulating antibody-secreting cells. J Infect Dis 1988;158:1011-6.
32. Schwartz E, Shlim DR, Eaton M, Jenks N, Houston R. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella Paratyphi A among foreigners in Nepal. Arch Intern Med 1990;150:349-51.
33. Simanjuntak CH, Paleologo FP, Punjabi NH et al. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 1991;338:1055-9.
34. Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P. Control of typhoid fever in Bangkok, Thailand, by annual immunization of schoolchildren with parenteral typhoid vaccine. Rev Infect Dis 1987;9:841-5.
35. Yang HH, Wu CG, Xie GZ et al. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China. Bull World Health Organ 2001;79:625-31.
36. Tacket CO, Ferreccio C, Robbins JB et al. Safety and immunogenicity of two Salmonella typhi Vi capsular polysaccharide vaccines. J Infect Dis 1986;154:342-5.
37. Kantele A. Peripheral blood antibody-secreting cells in the evaluation of the immune response to an oral vaccine. J Biotechnol 1996;44:217-24.
38. Ferreccio C, Levine MM, Rodriguez H, Contreras R. Comparative efficacy of two, three, or four doses of TY21a live oral typhoid vaccine in enteric-coated capsules: a field trial in an endemic area. J Infect Dis 1989;159:766-9.
39. Levine MM, Ferreccio C, Black RE, Germanier R. Large-scale field trial of Ty21a live oral typhoid vaccine in enteric-coated capsule formulation. Lancet 1987;1:1049-52.
40. Kantele A, Kantele JM, Arvilommi H, Mäkelä PH. Active immunity is seen as a reduction in the cell response to oral live vaccine. Vaccine 1991;9:428-31.
41. Forrest BD. Impairment of immunogenicity of Salmonella typhi Ty21a due to preexisting cross-reacting intestinal antibodies. J Infect Dis 1992;166:210-2.
42. Lycke N, Lindholm L, Holmgren J. Cholera antibody production in vitro by peripheral blood lymphocytes following oral immunization of humans and mice. Clin Exp Immunol 1985;62:39-47.
43. Kantele A, Savilahti E, Tiimonen H, Iikkanen K, Autio S, Kantele JM. Cutaneous lymphocyte antigen expression on human effector B cells depends on the site and on the nature of antigen encounter. Eur J Immunol 2003;33:3275-83.
44. Lue C, Tarkowski A, Mestecky J. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. J Immunol 1988;140:3793-800.
45. MacLennan CA, Gondwe EN, Msefula CL et al. The neglected role of antibody in protection against bacteremia caused by nontyphoidal strains of Salmonella in African children. J Clin Invest 2008;118:1553-62.
46. Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, Neutra MR. Monoclonal secretory immunoglobulin A protects mice against oral challenge with the invasive pathogen Salmonella typhimurium. Infect Immun 1992;60:1786-92.
47. Michetti P, Porta N, Mahan MJ et al. Monoclonal immunoglobulin A prevents adherence and invasion of polarized epithelial cell monolayers by Salmonella typhimurium. Gastroenterology 1994;107:915-23.
48. Endt K, Stecher B, Chaffron S et al. The microbiota mediates pathogen clearance from the gut lumen after non-typhoidal Salmonella diarrhea. PLoS Pathog 2010;6:e1001097.
49. Saxén H, Mäkelä O, Svenson SB. Isotype of protective anti-Salmonella antibodies in experimental mouse salmonellosis. Infect Immun 1984;44:633-6.
50. Saxén H. Mechanism of the protective action of anti-Salmonella IgM in experimental mouse salmonellosis. J Gen Microbiol 1984;130:2277-83.